Chemical formula: C₁₆H₁₄F₃N₅O Molecular mass: 349.311 g/mol PubChem compound: 71616
Voriconazole is indicated for:
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Treatment of invasive aspergillosis.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Treatment of candidaemia in non-neutropenic patients.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Treatment of candidaemia in non-neutropenic patients.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Voriconazole is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
